IRCT20190210042676N29
Recruiting
Phase 2
Evaluation of safety and effectiveness of an injectable solution containing deoxycholic acid with the brand name ®Embella, in order to reduce submental fat.
Zist orchid pharmed Company0 sites20 target enrollmentTBD
ConditionsSubmental fat.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Submental fat.
- Sponsor
- Zist orchid pharmed Company
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ages 18 to 65
- •People with unwanted submental fat with moderate to severe intensity, grades 2 and 3 of the clinical grade of SMF (submental fat) evaluation
- •Have signed the informed consent form and agree to a 3\-month follow\-up.
Exclusion Criteria
- •Any previous intervention to treat submental fat.
- •Specific anatomical features or previous damage to the intervention site (ulcers, liposuction, difficulty swallowing, enlargement of the thyroid gland or lymph nodes) that interfere with the evaluation of intervention results.
- •History of dysphagia
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Investigating the effect of stromal/mesenchymal stem cell-derived exosomes in patients with perianal fistulaIRCT20240128060828N1Tehran University of Medical Sciences30
Active, not recruiting
Not Applicable
Evaluacion de la eficacia y seguridad de la inyección intravítrea de triamcinolona en el tratamiento del edema difuso del diabético - Triamcinolona intravitreaDIFFUSE DIABETIC MACULAR OEDEMAEUCTR2005-001385-14-ESIOBA. FACULTAD DE MEDICINA
Completed
Not Applicable
Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for branch retinal vein occlusiobranch retinal vein occlusionJPRN-UMIN000018999Department of Ophthalmology, Shiga University of Medical Science40
Completed
Not Applicable
Evaluation of the efficacy, safety and injection interval of intravitreal injection of aflibercept for age-related macular degeneratioage-related macular degenerationJPRN-UMIN000019028Department of Ophthalmology, Shiga University of Medical Science40
Completed
Not Applicable
Evaluation of the efficacy, safety and injection interval of intravitreal injection of ranibizumab for retinal vein occlusioretinal vein occlusionJPRN-UMIN000012038Department of Ophthalmology, Shiga University of Medical Science50